News
Realizing the Full Potential of Diagnostic Testing in Cancer Care
View Story
How to Prevent the Next Pandemic: Antimicrobial Resistance
View Story
Juan Granados-Zúñiga, Lilly Pride Chair, Says ‘Be Yourself’
View Story
Updates: Lilly's Global COVID-19 Response
View Story
Progress in Migraine Care: Much to Celebrate, Much to Do
View Story
Indy Day of Solidarity – We Stand Together on June 13
View Story
June 25, 2020
Tags | Corporate
The fund, established by the Eli Lilly and Company Foundation, Lumina Foundation and Central Indiana Community Foundation, will focus on solutions that address racial inequities in the criminal justice system INDIANAPOLIS , June 25, 2020 /PRNewswire/ -- A coalition of local stakeholders has
June 24, 2020
Tags | Product
Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and
RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ® (empagliflozin) in
June 17, 2020
Tags | Product
INDIANAPOLIS , June 17, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine.